<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922594</url>
  </required_header>
  <id_info>
    <org_study_id>ZIKA_2016-102</org_study_id>
    <nct_id>NCT03922594</nct_id>
  </id_info>
  <brief_title>Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia</brief_title>
  <official_title>Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Pasteur du Cameroun</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Women and Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur de Côte d'Ivoire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur Ho Chi Minh City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tu Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Perinatal Society of Sri Lanka</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colombo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lausanne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health of Sri Lanka</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital Maternity</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Essos Hospital Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Baiyun Maternal and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Yopougon-Attie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital Abobo-Sud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Castle Street Hospital for Women</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>De Soyza Hospital for Women</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore whether ZIKV is currently responsible for neurological complications,
      and particularly microcephaly, in Aedes-infested regions of Sub-Saharan Africa (SSA) and
      Asia. This will inform regional public health strategies, such as vaccination of women of
      child-bearing age. It will also demonstrate the public health impact of ZIKV infection and
      increase the understanding of other regional infectious (e.g. cytomegalovirus) causes of
      microcephaly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will last for 2 years, and will include only new cases of microcephaly.

      Surveillance will take place in large maternities in urban areas (standard procedure)

        -  In each city, ~3000 live births per month will be monitored, so that on average one
           microcephaly will be diagnosed per month per city (i.e., 24 per city in 2 years)

        -  Microcephaly is defined as less than -3 standard deviation (SD), according to the
           INTERGROWTH standards by age and sex with abnormal ultrasound and/or clinical
           examination.

      Data collection (study activity)

        -  A questionnaire with demographic, exposure and pregnancy details for all mothers
           Clinical exam and laboratory testing (standard procedure and study activity)

        -  Various biological samples (e.g. blood, placenta) will be collected from mothers and
           newborns/fetuses and tested for presence of ZIKV, and for other infectious (e.g.
           rubella, cytomegalovirus) causes of microcephaly

        -  Physical, neurological, hearing and visual examinations for all live births will be
           performed where possible.

      Analysis and reporting (study activity)

      o All results will be shared publically through conferences and peer-reviewed publications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Days</target_duration>
  <primary_outcome>
    <measure>Incidence of microcephaly (per 10,000 live births)</measure>
    <time_frame>At birth</time_frame>
    <description>Incidence of microcephaly (per 10,000 live births)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of microcephaly attributable to ZIKV</measure>
    <time_frame>At birth</time_frame>
    <description>Proportion of microcephaly attributable to Zika virus infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of microcephaly linked to other infectious etiologies</measure>
    <time_frame>At birth</time_frame>
    <description>Proportion of microcephaly linked to other infectious etiologies (non-ZIKV)</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Microcephaly</condition>
  <condition>Congenital Infection</condition>
  <arm_group>
    <arm_group_label>Cameroon</arm_group_label>
    <description>Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns</description>
  </arm_group>
  <arm_group>
    <arm_group_label>China</arm_group_label>
    <description>Fetuses or newborns (still-born, medical abortions or alive) with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivory Coast</arm_group_label>
    <description>Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex and severely disproportionate length or weight according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sri Lanka</arm_group_label>
    <description>Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vietnam</arm_group_label>
    <description>Fetuses or newborns (still-born, medical abortions or alive) with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Differential diagnosis for infectious causes of microcephaly</intervention_name>
    <description>Zika virus, cytomegalovirus, rubella, toxoplasmosis</description>
    <arm_group_label>Cameroon</arm_group_label>
    <arm_group_label>China</arm_group_label>
    <arm_group_label>Ivory Coast</arm_group_label>
    <arm_group_label>Sri Lanka</arm_group_label>
    <arm_group_label>Vietnam</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Fetuses or newborns (still-born, medical abortions [China and Vietnam only] or alive) with
        microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for
        gestational age and sex with abnormal ultrasound and/or clinical examination findings for
        newborns.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All infants or fetuses with microcephaly, (defined as head circumference ≤-3SD
             according to INTERGROWTH standards for gestational age and sex, detected during the
             mother's pregnancy, or at the end of the mother's pregnancy at one of the
             participating maternities)

          -  and with abnormal ultrasound and/or clinical examination findings for newborns.

        Exclusion Criteria:

          -  Infants/fetuses with microcephaly whose mothers are under the age of 18 years,

          -  or inability or refusal of mothers/ guardians to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Days</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Fontanet</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Pasteur</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnaud Fontanet</last_name>
    <phone>+331 45 68 80 00</phone>
    <email>arnaud.fontanet@pasteur.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca Grant</last_name>
    <phone>+331 45 68 80 00</phone>
    <email>rebecca.grant@pasteur.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Hospital Maternity</name>
      <address>
        <city>Yaoundé</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florent Fouelifack Ymele</last_name>
    </contact>
    <investigator>
      <last_name>Florent Fouelifack Ymele</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essos Hospital Centre Maternity</name>
      <address>
        <city>Yaoundé</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Njom</last_name>
    </contact>
    <investigator>
      <last_name>Anne Njom</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Women's and Children's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiu (Sue) Qiu</last_name>
    </contact>
    <investigator>
      <last_name>Xiu (Sue) Qiu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Abobo-Sud</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Man-Koumba Soumahoro</last_name>
    </contact>
    <investigator>
      <last_name>Man-Koumba Soumahoro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Yopougon-Attie</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Man-Koumba Soumahoro</last_name>
    </contact>
    <investigator>
      <last_name>Man-Koumba Soumahoro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Castle Street Hospital for Women</name>
      <address>
        <city>Colombo</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kapila Jayaratne</last_name>
    </contact>
    <investigator>
      <last_name>Kapila Jayaratne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>De Soyza Hospital for Women</name>
      <address>
        <city>Colombo</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kapila Jayaratne</last_name>
    </contact>
    <investigator>
      <last_name>Kapila Jayaratne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tu Du Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thanh Binh</last_name>
    </contact>
    <investigator>
      <last_name>Than Binh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Cameroon</country>
    <country>China</country>
    <country>Côte D'Ivoire</country>
    <country>Sri Lanka</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Microcephaly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

